Prognostic significance of blood cell parameters in the treatment of small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2019.08.011

Abstract

Abstract: Small cell lung cancer is a special type of neuroendocrine tumor in the lungs, which has a poor therapeutic effect, and a short time for resistance to relapse, recurrence and distant metastasis. Therefore, searching for readily available predictive parameters is important for clinical treatment strategy. Some indicators of blood cell parameters have been extensively studied in malignant tumors such as non-small cell lung cancer, breast cancer, gastric cancer and colorectal cancer. Indepth understanding of the role of blood cell parameters in small cell lung cancer and its possible mechanisms are of great value in predicting the curative effect and prognosis of small cell lung cancer.

Key words: Small cell lung carcinoma, Treatment outcome, Forecasting, Blood cell parameters

Shen Xiabo, Wang Wei, Pan Yueyin. Prognostic significance of blood cell parameters in the treatment of small cell lung cancer[J]. Journal of International Oncology, 2019, 46(8): 496-499.

References

［1］ Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: small cell lung cancer, version 2.2018［J］. J Natl Compr Canc Netw, 2018, 16(10): 1171-1182. DOI: 10.6004/jnccn.2018.0079. ［2］ Hong J, Chen X, Gao W, et al. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab［J］. Cancer Manag Res, 2019, 11: 3371-3379. DOI: 10.2147/cmar.s187233. ［3］ Xue W, Tan P, Xu H, et al. Impact of the preoperative prognostic nutritional index on survival outcomes in upper tract urothelial carcinomas［J］. Cancer Med, 2019, 8(6): 2971-2978. DOI: 10.1002/cam4.2161. ［4］ Inamoto S, Kawada K, Okamura R, et al. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study［J］. Int J Colorectal Dis, 2019, 34(7): 1303-1315. DOI: 10.1007/s00384-019-03316-z. ［5］ Wen Q, Meng X, Xie P, et al. Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy［J］. Oncotarget, 2017, 8(46): 81405-81418. DOI: 10.18632/oncotarget.19073. ［6］ Suzuki R, Lin SH, Wei X, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer［J］. Radiother Oncol, 2018, 126(3): 499-505. DOI: 10.1016/j.radonc.2017.12.030. ［7］ Zheng Y, Wang L, Zhao W, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation［J］. Strahlenther Onkol, 2018, 194(12): 1152-1162. DOI: 10.1007/s00066-018-1362-7. ［8］ Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer［J］. Cell Biochem Biophys, 2014, 69(3): 633-640. DOI: 10.1007/s12013-014-9845-3. ［9］ Bernhardt D, Aufderstrasse S, Konig L, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy［J］. Cancer Manag Res, 2018, 10: 6563-6569. DOI: 10.2147/cmar.s180990. ［10］ Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer［J］. Br J Cancer, 2014, 111(3): 452-460. DOI: 10.1038/bjc.2014.317. ［11］ Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer［J］. Med Oncol, 2014, 31(12): 323. DOI: 10.1007/s12032-014-0323-y. ［12］ Cao S, Jin S, Shen J, et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients［J］. Oncotarget, 2017, 8(5): 8657-8669. DOI: 10.18632/oncotarget.14395. ［13］ Rades D, Kaesmann L, Janssen S, et al. A new score for estimating survival after definitive radiochemotherapy of limited disease small cell lung cancers［J］. Lung, 2016, 194(4): 625-629. DOI: 10.1007/s00408-016-9886-z. ［14］ Inomata M, Hayashi R, Tokui K, et al. Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy［J］. Tumori, 2014, 100(5): 507-511. DOI: 10.1700/1660.18164. ［15］ Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients［J］. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005. ［16］ Hong S, Zhou T, Fang W, et al. The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients［J］. Tumour Biol, 2015, 36(5): 3389-3397. DOI: 10.1007/s13277-014-2973-y. ［17］ Minami S, Ogata Y, Ihara S, et al. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer［J］. Lung Cancer (Auckl), 2017, 8: 249-257. DOI: 10.2147/lctt.s142880. ［18］ Go SI, Jeon H, Park SW, et al. Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer［J］. Thorac Cancer, 2018, 9(11): 1483-1491. DOI: 10.1111/17597714.12862. ［19］ Jin S, Cao S, Xu S, et al. Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy［J］. Clin Respir J, 2018, 12(9): 2433-2440. DOI: 10.1111/crj.12925. ［20］ Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review［J］. BMC Cancer, 2013, 13: 158. DOI: 10.1186/1471-2407-13-158. ［21］ He X, Zhou T, Yang Y, et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer［J］. Clin Lung Cancer, 2015, 16(6): e165-e171. DOI: 10.1016/j.cllc.2015.03.005. ［22］ Kim EY, Kim N, Kim YS, et al. Prognostic significance of modified advanced lung cancer inflammation index (ALI) in patients with small cell lung cancer_ comparison with original ALI［J］. PLoS One, 2016, 11(10): e0164056. DOI: 10.1371/journal.pone.0164056. ［23］ Mirili C, Guney IB, Paydas S, et al. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)［J］. Int J Clin Oncol, 2019, 24(2): 168-178. DOI: 10.1007/s10147-018-1338-8. ［24］ Tokunaga R, Nakagawa S, Miyamoto Y, et al. The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer［J］. Colorectal Dis, 2019, 21(1): 100-109. DOI: 10.1111/codi.14425. ［25］ Passiglia F, Galvano A, Castiglia M, et al. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients［J］. Ther Adv Med Oncol, 2019, 11: 1758835919839928. DOI: 10.1177/1758835919839928. ［26］ Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody［J］. Cancer Immunol Immunother, 2018, 67(3): 459-470. DOI: 10.1007/s00262-017-2092-x.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[3]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[8]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[9]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[10]	Wang Yaqian, Du Yiwei, Wang Xing, Jia Junmei. Prognostic predictors of immunotherapy in patients with small cell lung cancer [J]. Journal of International Oncology, 2023, 50(3): 179-182.
[11]	Huang Rui, Zhang Yunqing. Clinical efficacy of anlotinib monotherapy in second-line treatment of extensive stage small cell lung cancer with poor PS score [J]. Journal of International Oncology, 2023, 50(12): 705-710.
[12]	Wang Bing, Wang Aifu, Liu Wenshu, Fan Jiaojiao, Tian Weicheng, Wang Weili, Liu Boyu. The efficacy and safety of recombinant human thrombopoietin in the treatment of thrombocytopenia caused by tumor radiotherapy [J]. Journal of International Oncology, 2023, 50(11): 661-667.
[13]	Liu Song, Yu Guangji, Wang Qingdong. Efficacy and influencing factors of DEBIRI-TACE combined with regorafenib in the third-line or above treatment of colorectal cancer liver metastases [J]. Journal of International Oncology, 2022, 49(7): 400-407.
[14]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[15]	Ding Xinjing, Ding Jianghua. Research progress on the correlation between dermatological immune-related adverse events and clinical outcome of PD-1/PD-L1 inhibitors [J]. Journal of International Oncology, 2022, 49(4): 225-228.